Certain genetic variants, carried by around 10 percent of the population, could be making type 2 diabetes GLP-1 treatments (such as Ozempic and Wegovy) less effective, according to new research. These treatments are named after the glucagon-like peptide-1 (GLP-1) hormone that they simulate. In the case of diabetes , that means regulating blood sugar by boosting insulin and slowing down digestion. However, the impact of GLP-1 drugs on people with type 2 diabetes can vary considerably. The